Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Zanubrutinib

FDA-approved product (capsule, oral), marketed as Brukinsa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Zanubrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Mantle cell lymphoma
  • Neoplasm
  • Waldenstrom macroglobulinemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Zanubrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zanubrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

    NCT03465059 · start 2018-05-30

    Registered record
    Registry ID
    NCT03465059
    Conditions
    Hepatic Insufficiency & Healthy Subjects
    Interventions
    Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-30
    Completion
    2018-10-19
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Insufficiency & Healthy Subjects
    InterventionZanubrutinib
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

    NCT03206970 · start 2017-03-02

    Registered record
    Registry ID
    NCT03206970
    Conditions
    Refractory Mantle Cell Lymphoma; Relapsed Mantle Cell Lymphoma
    Interventions
    Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-02
    Completion
    2020-09-08
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Mantle Cell Lymphoma; Relapsed Mantle Cell Lymphoma
    InterventionZanubrutinib
    PhasePhase 2
    Registry statusCompleted

  • A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

    NCT02914938 · start 2016-10

    Registered record
    Registry ID
    NCT02914938
    Conditions
    Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Follicular Lymphoma (FL); Marginal Zone B Cell Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); High Grade Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma (MCL)
    Interventions
    ME-401; Rituximab; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2016-10
    Completion
    2023-03-29
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Follicular Lymphoma (FL); Marginal Zone B Cell Lymphoma +3 more
    InterventionME-401; Rituximab; Zanubrutinib
    PhasePhase 1
    Registry statusTerminated

  • Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

    NCT02795182 · start 2016-06-29

    Registered record
    Registry ID
    NCT02795182
    Conditions
    Lymphoma; Leukemia
    Interventions
    Zanubrutinib; Tislelizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06-29
    Completion
    2020-12-18
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Leukemia
    InterventionZanubrutinib; Tislelizumab
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects

    NCT04163523 · start 2016-05-25

    Registered record
    Registry ID
    NCT04163523
    Conditions
    Healthy Volunteers
    Interventions
    Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05-25
    Completion
    2016-07-21
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionZanubrutinib
    PhasePhase 1
    Registry statusCompleted